For intermittent fasting practitioners, this means maintaining optimal skin moisture even when dietary patterns change
Clinical trials, including the SURMOUNT-5 study, demonstrate tirzepatides ability to achieve 13.7-20.2% weight loss in individuals with obesity but without type 2 diabetes, outperforming other GLP-1 receptor agonists in direct comparisons
Millions of women have used them
On the other hand, Mounjaro delivers even greater metabolic benefits, with studies showing up to 20% weight loss, making it a formidable contender for both diabetes and obesity treatment
Total numbers of neurons and glial cells in cortex and basal ganglia of aged brains with Down syndromea stereological study
Established players compete through strong clinical nutrition expertise, premium protein formulations, broad retail distribution, and integrated wellness portfolios targeting GLP-1 users